Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 9

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

October 5, 2023

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: An Overview of Neuroblastoma

EP. 2: Approaches to Diagnosing Neuroblastoma

EP. 3: Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP. 4: Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP. 5: Differentiating Refractory and Relapsed Neuroblastoma

EP. 6: Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

EP. 7: Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

EP. 8: Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

Now Viewing

EP. 9: Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

EP. 10: Future Perspectives in the Treatment of Neuroblastoma